Ciprofloxacin Hydrochloride (CIPRO) Manufacturing
Manufacturing of Ciprofloxacin Hydrochloride (CIPRO) – Active Pharma Ingredient. Investment Opportunity for Startups and Entrepreneurs.
Ciprofloxacin is an antibiotic agent in the fluoroquinolone class used to treat bacterial infections such as urinary tract infections and pneumonia. Ciprofloxacin is FDA approved for the treatment of urinary tract infections, sexually transmitted infections (gonorrhea and cancroid), skin, bone and joint infections, prostatitis, typhoid fever, gastrointestinal infections, lower respiratory tract infections, anthrax, plague, and salmonellosis.
Related Projects: – Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing
Uses and Applications
Ciprofloxacin only treats bacterial infections; it does not treat viral infections such as the common cold. For certain uses including acute sinusitis, lower respiratory tract infections and uncomplicated gonorrhea, ciprofloxacin is not considered a first-line agent.
This antibiotic treats only bacterial infections. It will not work for virus infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
Mycoplasma contamination is a major problem in cell culture in biomedical and biopharmaceutical research, with rates near 15-30%. While there is no method for visual confirmation of mycoplasma, contamination has serious effects on key characteristics and functions of cells, thus compromising any research done. Cipro (ciprofloxacin hydrochloride) is the standard antibiotic for rapid and efficient decontamination.
Related Books: – Pharmaceutical, Drugs, Proteins Technology Handbooks
CIPRO is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis.
Ciprofloxacin (Cetraxal, Ciloxan, and Cipro) is an inexpensive drug used to treat certain bacterial infections. It is more popular than comparable drugs.
Application
Urogenital Infections
Respiratory Tract Infections
Gastrointestinal Infections
Typhoid
Bone and Joint Infections
Skin and Soft Tissue Infections
Sepsis and Other Systemic Infections
Related Videos: – Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs
Government Initiatives
- Some of the initiatives taken by the Government to promote the pharmaceutical sector in India are as follows:
- India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically by 2023.
- In November 2019, the Cabinet approved extension/renewal of extant Pharmaceuticals Purchase Policy (PPP) with the same terms and conditions while adding one additional product namely, Alcoholic Hand Disinfectant (AHD) to the existing list of 103 medicines till the final closure/strategic disinvestment of Pharma CPSUs.
- Under Budget 2020-21, Rs 65,012 crore (US$ 9.30 billion) has been allocated to the Ministry of Health and Family Welfare is. The Government has allocated Rs 34,115 crore (US$ 4.88 billion) towards the National Health Mission under which rural and urban people will get benefited.
- Rs 6,400 crore (US$ 915.72 million) has been allocated to health insurance scheme Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB-PMJAY).
- As per Economic Survey 2019-20, Government expenditure (as a percentage of GDP) increased to 1.6 per cent in FY20 from 1.2 per cent in FY15 on health.
Related Projects: – Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates
- The National Health Protection Scheme is the largest Government funded healthcare programme in the world, which is expected to benefit 100 million poor families in the country by providing a cover of up to Rs 5 lakh (US$ 7,723.2) per family per year for secondary and tertiary care hospitalisation. The programme was announced in Union Budget 2018-19.
- The Government of India is planning to set up an electronic platform to regulate online pharmacies under a new policy to stop any misuse due to easy availability.
- Government of India unveiled ‘Pharma Vision 2020’ to make India a global leader in end-to-end drug manufacture. Approval time for new facilities has been reduced to boost investment.
- India has imposed a provisional anti-dumping duty on imports of Ciprofloxacin Hydrochloride from China on the grounds that it was hurting domestic industry, following an investigation of the Directorate General of Trade Remedies (DGTR).
- The department of revenue issued a notification to the effect on September 2, imposing a duty ranging between $0.94 and $3.29 per kg coming from China.
- Ciprofloxacin Hydrochloride is used to treat different types of bacterial infections and certain types of diarrhea. The DGTR had initiated the investigation in January this year.
Related Videos: – Industrial, Medical and Specialty Gases Manufacturing Project Ideas
Market Outlook
The India ciprofloxacin market is segmented based on composition, source, and form, route of administration, distribution channel, application, end user, company and region. Based on route of administration, the market can be categorized into oral, ophthalmic, optic, and intravenous and others. The intravenous segment is expected to witness significant growth through FY2026. This can be ascribed to the use of this route of administration for the drugs which are not absorbed after consumption through oral route. Additionally, large quantities of drug can be administered using this route of drug administration with 100% bioavailability.
The Global Ciprofloxacin Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027.
Related Project:- Ciprofloxacin Hydrochloride
Indian pharmaceutical sector is expected to grow to US$ 100 billion, while medical device market is expected to grow US$ 25 billion by 2025. Pharmaceuticals export from India stood at US$ 20.70 billion in FY20. Pharmaceutical export include bulk drugs, intermediates, drug formulations, biological, Ayush and herbal products and surgical.
The remaining of the active pharmaceutical ingredient of ciprofloxacin is being dispersed in another combination product and specifically utilize in the urinary tract antibiotic only. Thereby anticipated to lure the new market players in the ciprofloxacin market. The higher incidence of skin and immunological disorder is anticipated to offer a steady revenue generation opportunity in the ciprofloxacin market. Increase awareness about safe drug utilization, however increase in adverse drug reaction awareness and stringent government impositions have narrowed the growth path for global Ciprofloxacin market in North America. Furthermore in East Asia region considerably higher market growth rate is expected due to higher utilization of ciprofloxacin in renal infection in the region. Thereby anticipated to increase the revenue generation in the Ciprofloxacin market.
Related Projects: – Chemicals (Organic, Inorganic, Industrial) Projects
The bulk drugs segment continues to be the highest revenue generating segment for the Indian pharma industry. It accounts for production worth Rs 120 bn and contributes about 36% of the total pharma exports. India produces 400 bulk drugs through its 1,300 licensed bulk drug units that cater to most of the domestic bulk drug requirements.
Related Projects: – Active Pharma Ingredients(API)
Key Players:-
- Aarti Drugs Ltd.
- Aurobindo Pharma Ltd.
- Cipla Ltd.
- Indoco Remedies Ltd.
- Kores (India) Ltd.
- Mylan Pharmaceuticals Pvt. Ltd.
- Neuland Laboratories Ltd.
- S S Organics Ltd
- Smruthi Organics Ltd.
- Sreepathi Pharmaceuticals Ltd.
- Sterling Basic Organics Ltd.
- Sun Pharma Laboratories Ltd.
- Sun Pharma Medisales Pvt. Ltd.
- Wockhardt Ltd.